By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tobira Therapeutics Inc. 

701 Gateway Boulevard
Suite 300
South San Francisco  California  94080  U.S.A.
Phone: 650-741-6625 Fax: n/a


Company News
Continuing Its String of Deals, Allergan (AGN) Buys Bay Area’s Tobira (TBRA) for $1.695 Billion 9/20/2016 6:13:48 AM
Tobira (TBRA) Announces Initiation Of Phase I Combination Study of Cenicriviroc And Evogliptin 9/12/2016 12:25:44 PM
Tobira (TBRA) Announces Appointment Of Dr. Laurent Fischer As Industry Co-Chair Of The Liver Forum Steering Committee 9/7/2016 1:11:09 PM
Tobira (TBRA) To Participate In Two Conferences In September 9/2/2016 10:21:24 AM
Tobira (TBRA) Reports Second Quarter 2016 Financial And Business Results 8/10/2016 11:03:24 AM
Tobira (TBRA) To Present At The 36th Annual Canaccord Genuity Growth Conference 8/2/2016 11:23:50 AM
Tobira (TBRA) To Host Conference Call At 8:30 A.M. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results 7/25/2016 9:30:42 AM
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss 7/25/2016 8:36:53 AM
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016 8:41:37 AM
Tobira’s Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology 6/17/2016 8:49:46 AM